Real Time qPCR (Q-PCR)

Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles^[1][2].

Two widely established fluorescence strategies are DNA-binding dyes and sequence-specific probes. SYBR Green I fluorescence increases upon binding double-stranded DNA and therefore reports accumulation of double-stranded amplification products, whereas hydrolysis-probe assays generate sequence-dependent fluorescence through probe hybridization and cleavage during amplification; because DNA-binding dyes also detect nonspecific double-stranded products, product specificity should be evaluated independently, for example by melting analysis and/or other amplicon-validation approaches^[2][3].

For gene-expression measurements, RNA is first reverse-transcribed into cDNA and the resulting cDNA is quantified by qPCR. Relative expression can be obtained by comparing a target with validated reference genes and a calibrator sample, whereas absolute quantification relates the qPCR signal to standards of known target quantity. The 2^{{-△△ Cq}} approach is applicable to relative expression when its amplification-efficiency assumptions are satisfied; when target and reference amplification efficiencies differ, efficiency-corrected models are more appropriate^[4][5][6].

The protocol below therefore describes a generic two-step RT-qPCR gene-expression workflow rather than a target-specific diagnostic assay. MIQE 2.0 emphasizes assay-specific validation, sample handling, controls, normalization, amplification performance, dynamic range and transparent analysis; consequently, a universal primer concentration, template quantity, cycling profile, Cq cutoff or limit of detection is not imposed here when the literature does not support a single value applicable to all assays^[7][8].

Total RNA and cDNA: total RNA is the starting material for transcript-expression analysis, and reverse transcription converts RNA into cDNA suitable for qPCR amplification. RNA extraction, storage, integrity, purity, genomic-DNA contamination and reverse-transcription procedures can influence downstream measurements and therefore constitute controlled parts of the RT-qPCR workflow^[7][8][9].

DNase, when required: contaminating genomic DNA can generate qPCR signal and bias transcript measurements, particularly when primers can amplify both genomic DNA and cDNA. DNase treatment is one strategy for reducing this contamination, although its effects on RNA recovery must also be considered^[8][9][10].

Nuclease-free water: water is required for reaction preparation and serves as the template replacement in no-template controls used to identify reagent or environmental contamination and nonspecific amplification^[7][8].

Forward and reverse primers: target-specific primers define the sequence amplified during PCR. Primer design and empirical validation are critical because off-target hybridization, primer dimers, secondary structures and unsuitable primer-binding properties can reduce specificity or technical precision; target specificity can be assessed computationally against relevant sequence databases before experimental validation^[11][12].

DNA-binding fluorescent dye such as SYBR Green I: the dye provides fluorescence proportional to formation of double-stranded amplification products and enables real-time monitoring; because it can also report nonspecific double-stranded products, amplification specificity must be evaluated^[2][3].

Alternatively, sequence-specific hydrolysis probes: probe-based qPCR provides an additional sequence-specific detection component because fluorescence generation depends on probe hybridization and cleavage during amplification^[2].

Reverse-transcription reagents: reverse transcriptase and the associated reaction components generate cDNA from RNA for two-step RT-qPCR; reverse-transcription conditions must be documented because this enzymatic step contributes experimental variability^[7][8][9].

qPCR reaction mixture: a thermostable DNA polymerase, reaction buffer, dNTPs and appropriate fluorescent chemistry support amplification and real-time detection. The exact formulation and concentrations should correspond to the experimentally validated assay rather than being treated as universally interchangeable conditions^[7][8][11].

Equipment and instruments

Real-time PCR thermocycler: the instrument performs thermal cycling while collecting fluorescence measurements during amplification and is therefore required for Cq determination and amplification-curve acquisition^[1][2].

RNA/cDNA quantification and RNA-quality assessment instrumentation: assessment of nucleic-acid quantity, purity and RNA integrity is part of quality-controlled RT-qPCR workflows, particularly for experiments intended to compare transcript abundance among biological samples^[7][8][9].

Standard molecular-biology equipment: calibrated pipettes, PCR-compatible reaction vessels and centrifugation equipment are required for reproducible sample and reaction preparation, and relevant equipment and reaction details should be documented sufficiently to permit experimental reproduction^[7][8].

3.1 Preparation Steps

Step 1 — Define the target and biological comparison. Select the transcript(s), experimental groups and biological samples before assay optimization. For relative gene-expression experiments, candidate reference genes must be evaluated under the actual biological and experimental conditions rather than assuming that a conventional housekeeping gene is invariant^[7][13][14].

Step 2 — Design or select primers. Design primers against the intended transcript sequence and evaluate target specificity computationally. Primer-design methods should consider target specificity, primer secondary structure and primer-dimer formation; for RT-qPCR, exon-aware primer placement can also help distinguish transcript-derived cDNA from genomic DNA when the target structure permits it. Candidate assays must subsequently be validated experimentally because computational design alone does not establish qPCR performance^[11][12].

Step 3 — Extract RNA. Isolate total RNA using a validated extraction method while maintaining consistent sample collection, processing and storage across experimental groups. Evaluate RNA quantity and quality before reverse transcription, because variation introduced before qPCR cannot be corrected simply by downstream amplification^[7][8][9].

Step 4 — Evaluate genomic-DNA contamination. Include a no-reverse-transcription control (no-RT control) when genomic DNA could contribute to the qPCR signal. If contaminating DNA is demonstrated and the assay cannot discriminate cDNA from genomic DNA by primer design, an experimentally validated DNA-removal strategy may be required^[7][8][10].

Step 5 — Reverse transcribe RNA. Convert RNA to cDNA using a defined reverse-transcription procedure and apply the same validated RNA input and reaction conditions across samples intended for quantitative comparison. Reverse transcription is an important source of variability and should therefore be performed and documented consistently^[7][8][9].

3.2 Operation Steps

Step 1 — Validate the qPCR assay before experimental quantification. Determine assay specificity, amplification behavior, usable quantitative range and amplification efficiency using appropriate dilution-series experiments. Current MIQE recommendations favor converting Cq measurements to efficiency-corrected target quantities and documenting the assay's dynamic range and detection characteristics rather than assuming identical amplification behavior for every primer pair^[7][8].

Step 2 — Prepare the qPCR reaction mixture. Combine the validated qPCR chemistry with target-specific forward and reverse primers and template cDNA; prepare corresponding controls using the same reaction formulation. Primer concentration and other reaction parameters should be empirically optimized for the individual assay because primer design and reaction conditions interact to determine specificity and precision^[8][11].

Step 3 — Include controls on the experimental plate. Include no-template controls to detect contamination or reagent-associated amplification and no-RT controls when residual genomic DNA could contribute to the signal. For assays requiring quantitative calibration, include appropriate standards spanning the validated quantitative range^[7][8][10].

Step 4 — Run real-time amplification. Perform denaturation, primer annealing and extension under the thermal profile validated for the primer pair and qPCR chemistry while collecting fluorescence during amplification. Because optimal annealing/extension conditions depend on primer sequence, amplicon and reaction chemistry, a single universal temperature/time profile is not specified here^{[2][7][8][11]}.

Step 5 — For DNA-binding-dye assays, evaluate product specificity after amplification. Melting-curve analysis can distinguish products according to their thermal dissociation behavior and is useful for detecting additional products or primer-associated artifacts; early SYBR Green qPCR studies combined amplification curves with melting analysis and independent product verification to establish assay specificity^[2][3].

3.3 Data Acquisition and Analysis

Inspect amplification curves and control reactions before biological interpretation. A valid experiment requires behavior consistent with the validated assay: no-template controls are used to detect contamination/nonspecific amplification, no-RT controls evaluate RNA preparations for amplification attributable to genomic DNA, and assay-specific standards or other positive controls can verify expected amplification where applicable. Raw fluorescence and analysis settings should be retained where possible so that Cq determination and downstream calculations remain inspectable^[7][8].

For relative gene-expression analysis, normalize target measurements using reference genes whose expression stability has been demonstrated in the relevant samples. Vandesompele and colleagues showed that normalization using the geometric mean of multiple validated internal-control genes can reduce errors associated with relying on a single unvalidated housekeeping gene; subsequent studies likewise demonstrated that suitable reference genes depend on biological context^[13][14].

The 2^{{-△△ Cq}} method expresses target abundance relative to a reference and calibrator under its stated assumptions. When amplification efficiencies differ, use an efficiency-corrected calculation such as the Pfaffl model or an equivalent validated framework rather than treating all reactions as having identical efficiency^[4][5][6].

Biological replicates represent independent biological samples and should form the basis of biological inference, whereas technical replicate reactions primarily characterize measurement precision. Experimental design, replicate structure, excluded reactions and statistical methods should be documented explicitly rather than treating multiple PCR wells from one biological sample as independent biological observations^[7][8].

For absolute quantification, relate unknown samples to calibrated standards within the assay's validated quantitative range. For relative quantification, report normalized quantities or fold changes together with the normalization method, amplification-efficiency treatment and uncertainty/statistical analysis; MIQE 2.0 specifically emphasizes efficiency-corrected target quantities, detection limits, dynamic ranges and appropriate uncertainty reporting^[4][7].

Amplification is observed in the no-template control.

Possible Cause: contaminating nucleic acid or formation of nonspecific/primer-dimer products can generate fluorescence, particularly with DNA-binding-dye assays.

Solution: examine amplification and melting behavior, verify product specificity, review primer design and repeat the assay after eliminating the identified contamination or nonspecific-amplification source; primers should be empirically validated rather than accepted solely from in-silico design^[2][7][11].

More than one melting feature is observed in a SYBR Green assay.

Possible Cause: SYBR Green reports double-stranded DNA independently of sequence, so off-target products or primer-associated products may contribute fluorescence.

Solution: reassess primer specificity and reaction conditions and confirm the intended amplicon independently during assay validation; only measurements from an assay demonstrated to generate the intended specific product should be used quantitatively^[2][3][11].

Amplification is detected in a no-RT control.

Possible Cause: residual genomic DNA in the RNA preparation can be amplified when the assay recognizes both genomic DNA and cDNA.

Solution: redesign the assay to discriminate transcript-derived cDNA where sequence structure permits, or use and validate a DNA-removal procedure while monitoring its effect on RNA recovery^[7][10][12].

Apparent fold changes depend strongly on the chosen housekeeping gene.

Possible Cause: the reference gene is not stably expressed under the tested biological conditions.

Solution: experimentally evaluate candidate reference genes in the relevant sample set and normalize with multiple validated stable reference genes where appropriate rather than assuming that GAPDH, ACTB or another conventional housekeeping gene is universally stable^[13][14].

Target and reference assays yield substantially different amplification efficiencies.

Possible Cause: primer sequence, amplicon properties and reaction conditions can produce assay-dependent amplification behavior.

Solution: experimentally determine amplification efficiency, optimize the assays where appropriate and use efficiency-corrected relative quantification rather than an analysis that assumes equivalent amplification efficiencies^{[5][6][7][11]}.